Published on June 29, 2016 at 3:06 AM
Recent studies on a little variety of patients along with leukemia treated along with bone marrow transplantation have actually suggested that the presence of the common cytomegalovirus (CMV) in patients or their donors might protect versus relapse or also death after the transplant. A huge global study published in the diary Blood, based on data from some 9,500 transplant patients in over 400 hospitals in between 2003 and 2010 now shows the opposite. “The original purpose of the study was to confirm that CMV infection might stay clear of leukemia relapse, stay clear of death, and come to be a severe therapeutic device for boosting patient survival rates,” said Dr. Pierre Teira, hematologist-oncologist and researcher at the mother-kid study hospital CHU Sainte-Justine, assistant clinical professor at the University of Montreal’s Faculty of Medicine, and initial author of the study. “However, we discovered the exact opposite. Our outcomes clearly prove to that, despite substantial development earned in the last twenty years in the fight versus death straight related to CMV, the virus not just does not stay clear of leukemia relapse, yet additionally remains a severe factor associated along with the risk of death. Monitoring of CMV after transplantation remains a priority for patients.”
CMV is a common virus in the overall population. Indeed, much more compared to 90% of adults are carriers. In healthy and balanced people, CMV infection normally goes unnoticed, even though the virus remains along with them in latency throughout their lives. However, in leukemia patients receiving bone marrow transplants, CMV infection improves the risk of death. Yet, reactivation of CMV after a transplant is rapidly detected and easily treated by current antiviral drugs. “Deaths because of uncontrolled CMV reactivation are nearly zero in this study, so uncontrolled CMV reactivation is not exactly what reduces survival paces after transplantation. The link in between this common virus and increased risk of death remains a biological mystery,” said Dr. Teira.
One feasible explanation is that CMV decreases the ability of the transplant patient’s immune system to fight versus various other kinds of infection. This is supported by the honest truth that death paces from infections various other compared to CMV are greater in patients infected along with CMV, or whose donors were. For researchers, the next step is therefore to verify whether the most recent generation of anti-CMV treatments can easily stay clear of the two reactivation of the virus and weakening of the patient’s immune system versus various other kinds of infection in the presence of CMV infection. “CMV has actually a complex impact on the outcomes for transplant patients, and each year much more compared to 30,000 patients about the globe get bone marrow transplants from donors. It is therefore important for future study to much better know the role played by CMV after bone marrow transplantation and increase the opportunities of victory of the transplant. This will certainly advice to much better go for the ideal donor for the ideal patient,” concluded Dr. Teira.
